{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P03973",
      "entity_text" : "ALP",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ],
      "TissueType" : [ "tissuelist:TS-0564" ],
      "Organ" : [ "uberon:UBERON:0000468" ],
      "CellType" : [ "cl:CL:1000488" ]
    }
  },
  "verbose_text" : "Phase II clinical trials in humans have yielded favorable results, with evidence that 24-norUDCA dramatically decreases ALP levels in a dose dependent manner [XREF_BIBR].",
  "reading_complete" : "2020-08-04T11:08:39Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T10:58:07Z",
  "trigger" : "levels",
  "evidence" : [ "ALP levels" ],
  "pmc_id" : "6319937",
  "score" : 0
}